From Investing.com: 2024-04-10 17:05:48

The U.S. Justice Department has filed a false claims act complaint against Regeneron Pharmaceuticals for allegedly filing false average sales price reports, accusing the company of not reporting price concessions on its drug Eylea used for treating neovascular Age-Related Macular Degeneration.

Regeneron is accused of manipulating Medicare’s drug pricing process, leading to inflated costs of its drug to Medicare and increased revenues. The company allegedly failed to report payment of credit card processing fees as price concessions to customers.

A spokeswoman for Regeneron has not responded to requests for comment on the allegations made by the U.S. Justice Department regarding their drug pricing practices.



Read more at Investing.com: US Justice department files complaint against Regeneron, alleges fraudulent drug pricing By Reuters